Editorial Staff

Study Finds Pandemic Likely to Negatively Impact Biopharmaceutical Sector

/in , , , , , , /by Editorial Staff
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Threats to intellectual property, political pressure to lower prices, disruption of clinical trials will cause long-term harm

BOSTON – Contrary to conventional wisdom that says the coronavirus pandemic will generally benefit biopharmaceutical companies, a new Pioneer Institute study finds many companies will emerge from the pandemic commercially weaker, dealing with delays in new product launches and with fewer resources to invest in research and development.

“There will certainly be worldwide demand for COVID-19 treatments,” said William Smith, author of “The Negative Impact of COVID-19 Upon the Biopharmaceutical Sector.”  “But they will also require massive investments in clinical development and manufacturing, and political pressure on pricing makes it impossible for companies to recoup those investments.”

Cipro is an antibiotic well-suited to treat anthrax, which began arriving in mailboxes in the weeks after September 11, 2001.  The Centers for Disease Control recommends that patients exposed to the bacteria take Cipro twice a day for 60 days.  Despite the fact that the entire course of treatment would only cost $219, Bayer agreed to cut the price in half after the U.S. Secretary of Health and Human Services at that time threatened to take away the company’s patent.

More recently, when Gilead announced it would invest $1 billion in Remdesivir, a promising COVID-19 treatment, one would have thought the company’s stock would rise.  Instead, it fell 5 percent.  A number of analysts remarked that the reason was fears that political pressure would result in very low prices or threats to Gilead’s patent.

Some investors and industry leaders may conclude that investments in major public health emergencies should be avoided in favor of research on lifestyle treatments or medications for less serious conditions that aren’t accompanied by threats to intellectual property or pressure to reduce prices.

Political pressure to cut prices is likely to be most acute in the area of vaccines, where the federal government is providing grants to companies such as Johnson & Johnson and Moderna.  Many policymakers will likely see any new vaccine that emerges from research that was partially funded by the government as public property.

“There may be humanitarian reasons why companies choose not to profit from their treatments,” said Pioneer Executive Director Jim Stergios.  “But policymakers should also be aware that threats to intellectual property create significant disincentives to investment.”

In 2018, Massachusetts institutions received nearly $3 billion in National Institutes of Health funding, the second highest amount among the states.  That same year, private venture companies invested $4.8 billion in the Commonwealth’s life sciences companies.  In terms of new businesses, more than a third of U.S.-based biotechs that went public in the first half of 2019 were Massachusetts-based.

These companies also face delays in clinical trials for non-COVID-19 treatments, which could significantly disrupt long-term product pipelines.  Since firms typically file patents before clinical trials begin, significant delays eat up the period during which treatments can be sold under patent before opening up to competition from generic makers.

The delays are particularly damaging to small firms, whose future may depend on a successful trial.

Smith’s recommendations include extending patent life on products by the period clinical trials were delayed by the pandemic, and that COVID-19 treatments in which companies made significant investments should be priced to allow a reasonable return on that investment.

About the Author

Dr. William S. Smith is Visiting Fellow in Life Sciences at Pioneer Institute. He writes about public policy issues impacting the life sciences industry with particular emphasis upon pharmaceuticals. Dr. Smith has 25 years of experience in government and in corporate roles. He spent ten years at Pfizer as Vice President of Public Affairs and Policy. He later served as a consultant to major pharmaceutical, biotechnology and medical device companies, and was President of a small medical device company for three years. His career has also included senior staff positions for the Republican House leadership on Capitol Hill, the White House, and in the Governor’s office in Massachusetts. He is affiliated as Research Fellow and Managing Director with the Center for the Study of Statesmanship at The Catholic University of America (CUA). He earned his PhD at CUA and a bachelor’s degree from Georgetown University.

About Pioneer

Mission
Pioneer Institute develops and communicates dynamic ideas that advance prosperity and a vibrant civic life in Massachusetts and beyond.

Vision
Success for Pioneer is when the citizens of our state and nation prosper and our society thrives because we enjoy world-class options in education, healthcare, transportation and economic opportunity, and when our government is limited, accountable and transparent.

Values
Pioneer believes that America is at its best when our citizenry is well-educated, committed to liberty, personal responsibility, and free enterprise, and both willing and able to test their beliefs based on facts and the free exchange of ideas.

Get Our COVID-19 News, Tips & Resources!

  • This field is for validation purposes and should be left unchanged.

Related Content

Targeted government help for small business is needed

0 Comments
/
Covid-19 will frame economic policy discussions for years to come, just as the Great Recession did a decade ago. The economic impact of the pandemic includes widespread job losses, and millions of Americans are at risk of falling into poverty. Covid-19 is also accelerating pre-existing market trends – such as automation and online shopping – and their potentially devastating impact on the thousands of small businesses vulnerable to these market shifts. Will these businesses be able to adapt?

MCAS testing essential to address falling test scores

0 Comments
/
Amid the chaos that was created by schools suddenly being shuttered in March as a result of the COVID-19 pandemic, it made sense to cancel administration of Massachusetts Comprehensive Assessment System (MCAS) tests. But supporters of pending legislation that would place a four-year moratorium on using MCAS as a high school graduation requirement and create a commission to study alternatives to the tests are no longer responding to a crisis; they are using it to advance their anti-reform agenda.

Wall Street Journal Columnist Jason Riley on the 2020 Election, School Choice, & Race in America

0 Comments
/
This week on “The Learning Curve,” Cara and Gerard are joined by Jason Riley, a senior fellow at the Manhattan Institute and columnist for The Wall Street Journal. Jason shares insights on the 2020 election, its implications for the next two years, and assuming Vice President Biden becomes president, how he may govern on K-12 education.

Disputing Democracy – 5 Contentious U.S. Presidential Elections – Resources for K-12 Education

In Pioneer’s ongoing series of blogs, on curricular resources for parents, families, and teachers during COVID-19, this one focuses on: Introducing K-12 schoolchildren to the great, contentious presidential elections in U.S. history.

Pioneer Institute Statement on Governor Baker’s New COVID Restrictions

Read Pioneer Institute's public statement about Gov. Charlie Baker's new executive orders related to the state’s reopening plan that will go into effect on Nov. 6, issued in response to a significant uptick in COVID infections in Massachusetts,

Voting for Health: Party Opinions, Election Results & the Healthcare Policy Implications of Election 2020

0 Comments
/
Join Host Joe Selvaggi as he discusses with Harvard Professor Bob Blendon his New England Journal of Medicine Special Report, "Implications of the 2020 Election for U.S. Health Policy," which covers broad differences in both party’s view of the role of government in health care and what the election results will mean for Americans.

Hockey Sidelined Again

0 Comments
/
After months on the sidelines, youth hockey players across the state eagerly laced up their skates in August. Under current youth and amateur sports guidelines, locker rooms operate at 50 percent capacity, only one spectator should attend per player, and players wear masks on the bench. Unlike in MIAA high school sports, players do not wear facemasks while they play, except during faceoffs. 

“Double, Double Toil and Trouble” – 15 Halloween Resources for K-12 Students

In Pioneer’s ongoing series of blogs here, on curricular resources for parents, families, and teachers during COVID-19, this one focuses on: Introducing K-12 students to the history behind Halloween.

Staving Off Disaster: Lessons from Covid Applied to the Epic Battle Against Drug Resistant Microbes

0 Comments
/
Join Hubwonk host Joe Selvaggi and Pioneer Institute’s Bill Smith as they discuss with inspirational public health advocate Gunnar Esiason the findings of his latest white paper, "Antimicrobial Resistance: Learning From the current health crisis to inform another."  The episode looks at the challenges to global health presented by evolving drug resistant diseases and how the lessons learned from COVID-19 could potentially save millions of lives.

The Commonwealth of Health -Massachusetts’s Great Medical Innovations – 15 Resources for High School Students

In Pioneer’s ongoing series of blogs here, on curricular resources for parents, families, and teachers during COVID-19, this one focuses on: Introducing high school students to great medical innovations from Massachusetts.

NCTQ’s Kate Walsh on the Crisis in K-12 Teacher Prep, Quality, & Evaluation

0 Comments
/
This week on “The Learning Curve,” Cara and Gerard are joined by Kate Walsh, president of the National Council on Teacher Quality. They discuss the qualifications of those who enter the teaching profession, explore teacher preparation, and key differences between teacher preparation, accreditation, and job prospects in the U.S. and other countries. They also speculate about what a Biden presidency might mean for K-12 education policymaking, and discuss how to diversify the teaching pipeline.

The Republic of Gadgets – America’s Great Inventors – 25 Resources for K-12 Education

Understanding the enduring public and private benefit that great inventors and their contraptions have made to our civilization is to better appreciate the connections between human necessity, creativity, and ingenuity. Yet, in American K-12 education very little focus is placed on studying who America’s great inventors were and the central role they’ve played in shaping our republic of gadgets. We’re offering a variety of links on the topic for parents, teachers, and schoolchildren to enjoy and better realize authentic innovators.